MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-05-2023
Heska Corporation Operating Income 2011-2026 | HSKA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -20.3 M | -993 K | -8.19 M | 327 K | 3.79 M | 18.2 M | 16.5 M | 8.56 M | 2.91 M | -1.43 M | 2.16 M | 3.25 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.2 M | -20.3 M | 2.07 M |
Quarterly Operating Income Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.4 M | - | -671 K | -5.54 M | -11.5 M | - | -2.43 M | -694 K | 1.02 M | - | 203 K | -4.45 M | -4.62 M | 775 K | 193 K | -566 K | -75 K | 3.31 M | -3.6 M | 2.2 M | 1.87 M | 7.09 M | 3.78 M | 4.56 M | 2.79 M | 6.52 M | 4.49 M | 3.56 M | 1.97 M | 3.56 M | 2.14 M | 1.83 M | 1.02 M | 1.75 M | 341 K | 917 K | -101 K | 2.76 M | 75 K | -3.58 M | -682 K | 720 K | -27 K | 383 K | 1.08 M | 414 K | 408 K | 887 K | 1.54 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.09 M | -11.5 M | 332 K |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 18.56 | - | $ 196 M |  China |
 |
Agilent Technologies
A
|
1.35 B | $ 113.26 | - | $ 34.4 B |  USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.63 | - | $ 2.17 M | USA |
 |
Castle Biosciences
CSTL
|
-42.8 M | $ 18.88 | - | $ 547 M | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 16.19 | - | $ 490 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.8 | -5.26 % | $ 7.96 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 20.49 | - | $ 1.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-2.37 M | - | - | $ 9.42 M |  Israel |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 96.67 | - | $ 6.52 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 419.17 | - | $ 12.1 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Myriad Genetics
MYGN
|
-387 M | $ 3.62 | - | $ 335 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.36 | - | $ 1.07 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 18.93 | - | $ 424 M | USA |
 |
Natera
NTRA
|
-541 M | $ 196.91 | - | $ 19.4 B | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 159.12 | - | $ 7.89 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 25.5 | - | $ 24.2 B |  Niderland |
 |
Guardant Health
GH
|
-437 M | $ 98.66 | - | $ 12.4 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 5.82 | - | $ 243 M | USA |
 |
Personalis
PSNL
|
-88.1 M | $ 6.71 | - | $ 599 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 117.09 | - | $ 9.66 B |  Irlanda |
 |
Illumina
ILMN
|
-833 M | $ 143.24 | - | $ 22.8 B | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.99 | - | $ 2.69 B | USA |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.41 | - | $ 5.54 M | USA |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 448.21 | - | $ 169 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 254.02 | - | $ 21.1 B | USA |
 |
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.58 | - | $ 208 M | Irlanda |
 |
Celcuity
CELC
|
-172 M | $ 134.72 | - | $ 6.3 B | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 52.95 | - | $ 3.17 B | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 8.43 | - | $ 1.83 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 187.94 | - | $ 20.9 B | USA |